Tests dapagliflozin early in patients having a heart attack
Tests early dapagliflozin, or placebo, in adults having a heart attack.
Plain-language title generated from the registry record
Registry title: Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Key facts
- Where
- Shibīn al Kawm, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06009874, who can take part
Where in Egypt
- Mohammad SolimanShibīn al Kawm, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mohammad Hussien Tantawy Soliman
- Trial code
- NCT06009874
- Record updated
- 14 October 2026
- Original description
This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.Read full original descriptionShow less
Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction
This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.
Inclusion: Patients with ST-elevation myocardial infarction (STEMI); STEMI was defined according to the Fourth Universal Definition of AMI; 18 - 80 years of age; Diabetics or non-diabetics; eGFR > 45 ml/min/1.73m2; Blood pressure before first drug dosing >110/70 mmHg.
Exclusion: Previous coronary artery bypass surgery; Patients currently on or have received any SGLT-2 inhibitors; History of diabetic ketoacidosis; Genital and urinary infections; History of AMI; Stent thrombosis; Severe hepatic insufficiency; Advanced cancer patients; Known allergy to SGLT-2 inhibitors; Cardiogenic shock; Hypoglycemia; Blood pH < 7.32; Hemodynamic instability; Females of childbearing potential without adequate contraceptive methods.